GC
ABCL icon

Gruss & Co’s AbCellera Biologics ABCL Stock Holding History

Gruss & Co’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-100,000
Closed -$646K – 18
2023
Q2 		$646K Sell
100,000
-67,500
-40% -$461K 3.92% 12
2023
Q1 		$1.26M Sell
167,500
-87,900
-34% -$798K 7.99% 5
2022
Q4 		$2.59M Sell
255,400
-53,170
-17% -$614K 15.98% 1
2022
Q3 		$3.05M Sell
308,570
-55,208
-15% -$606K 26.27% 1
2022
Q2 		$3.87M Buy
363,778
+77,778
+27% +$659K 26.99% 1
2022
Q1 		$2.79M Sell
286,000
-140,966
-33% -$1.33M 12.38% 1
2021
Q4 		$6.11M Sell
426,966
-3,441
-0.8% -$52.2K 16.39% 1
2021
Q3 		$8.63M Buy
+430,407
New +$7.61M 24.12% 1

Other funds holding ABCL

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
FFVM
Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Gruss & Co's ABCL Position: Q3 2023 in Review

Gruss & Co sold out of AbCellera Biologics (ABCL) in Q3 2023, closing a stake of 100,000 shares — an estimated $646K sold.

Gruss & Co first reported a position in ABCL in Q3 2021 and held it in 8 quarters. The position peaked at $8.63M in Q3 2021. 138 funds tracked by Wall St. Rank hold ABCL as of Q3 2023.

  • Gruss & Co reported no remaining AbCellera Biologics position as of Q3 2023 after selling out during the quarter.
  • Gruss & Co sold 100,000 AbCellera Biologics shares in Q3 2023, an estimated $646K.
  • Gruss & Co first reported a position in AbCellera Biologics in Q3 2021 and held it in 8 quarters.
  • Gruss & Co's AbCellera Biologics position peaked at $8.63M in Q3 2021.
  • 138 funds tracked by Wall St. Rank held AbCellera Biologics as of Q3 2023.

Based on Gruss & Co's 13F filing for Q3 2023, filed 13 Nov 2023.